2017 Opioid and Other Substance Use Disorders Final Report
Final Report to the Colorado General Assembly by the Opioid and Other Substance Use Disorders Interim Study Committee.
Second Regular Session | 73rd General Assembly
Colorado General AssemblyFinal Report to the Colorado General Assembly by the Opioid and Other Substance Use Disorders Interim Study Committee.
Legislative Emergency Preparedness, Response, and Recovery Final Report for 2017.
This memorandum addresses patient access to experimental treatments, including access to clinical trials, participation in the U.S. Food and Drug Administration’s Expanded Access (Compassionate Use) Program, and access to treatments under Colorado’s Right to Try Act. Additionally, this...
This issue brief addresses the state’s emergency mental health hold procedure, which allows for a person to be involuntarily held for a 72-hour period of treatment and evaluation if he or she appears to have a mental illness and, due to the mental illness, appears to be an imminent danger to...
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its September 2017 meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its September 2017 meeting.
Presented to the Opioid and Other Substance Use Disorder Interim Study Committee at its September 2017 meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its September 2017 meeting.
Presented to the Opioid and Other Substance use Disorders Interim Study Committee at its September 2017 meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its September 2017 meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its September 2017 meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its September 2017 meeting.
Presented to the County Courthouse and County Jail Funding and Overcrowding Solutions Interim Study Committee at its July 2017 committee.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its September 2017 meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its September 2017 meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Committee Study Committee at its August 1, 2017 meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its August 1, 2017 meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its August 1, 2017, meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its August 1, 2017, meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its August 1, 2017, meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its August 1, 2017, meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Committee at its August 1, 2017, meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its August 1, 2017, meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its August 1, 2017, meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its August 1, 2017, meeting.